Pfizer/BioNTech COVID-19 vaccine shows 90.7% efficacy in trial in children

The Pfizer/BioNTech COVID-19 vaccine showed 90.7% efficacy against the coronavirus in a clinical trial of five to 11 year olds, the U.S. drugmaker said on Friday.


Reuters | New York | Updated: 22-10-2021 17:41 IST | Created: 22-10-2021 17:31 IST
Pfizer/BioNTech COVID-19 vaccine shows 90.7% efficacy in trial in children
Representative image Image Credit: ANI
  • Country:
  • United States

The Pfizer/BioNTech COVID-19 vaccine showed 90.7% efficacy against the coronavirus in a clinical trial of five to 11-year-olds, the U.S. drugmaker said on Friday. Sixteen children in the trial who had received a placebo got COVID-19, compared with 3 who were vaccinated, Pfizer said in briefing documents submitted to the U.S. Food and Drug Administration.

Because more than twice as many children in the 2,268-participant trial were given the vaccine than placebo, that equates to better than 90% efficacy. Outside advisors to the FDA are scheduled to meet on Tuesday to vote on whether to recommend that the agency approve the vaccine for that age group.

 

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback